Related Experiment Video
Updated: Jun 18, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Proteomics for brain disorders--the promise for biomarkers
Malcolm Ward1, Andreas Güntert, James Campbell
1Proteome Sciences plc, London, United Kingdom. malcolm.ward@proteomics.com
Annals of the New York Academy of Sciences
|November 13, 2009
Summary
Proteomics offers a promising avenue for discovering novel brain disorder biomarkers. Continued collaboration and multidisciplinary efforts are crucial for overcoming challenges and realizing this potential for improved diagnostics and treatments.
Area of Science:
- Neuroscience
- Biochemistry
- Biotechnology
Background:
- Urgent need for reliable biomarkers in brain disorder diagnosis, progression monitoring, and treatment response assessment.
- Proteomics enables the discovery of biochemical markers through protein and peptide alterations.
- Existing proteomics efforts have yielded limited qualified biomarkers for neurological conditions.
Purpose of the Study:
- To review challenges and discuss strategies for proteomics in biomarker discovery for brain disorders.
- To foster optimism and outline requirements for successful biomarker development in neuroscience.
- To highlight the importance of interdisciplinary collaboration in advancing brain disorder research.
Main Methods:
- Review of discussions from proteomics breakout sessions at the Biomarkers for Brain Disorders conference (Oxford, January 2009).
- Analysis of challenges and opportunities in applying proteomics to neurological disease research.
- Synthesis of expert opinions on the future of proteomics-based biomarker discovery.
Main Results:
- Identified numerous challenges hindering the translation of proteomics findings into clinical biomarkers.
- Highlighted the potential of proteomics to detect changes in protein concentration and post-translational modifications.
- Emphasized the need for robust validation and standardization in proteomics studies.
Conclusions:
- Proteomics holds significant promise for identifying novel biomarkers for brain disorders.
- Overcoming current challenges requires multidisciplinary teams and strong academic-industry partnerships.
- Continued investment and collaborative research are essential for realizing the clinical utility of proteomics in neurology.
Related Concept Videos
01:33Proteomics
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
01:14Brain Imaging
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).